Arthritis, Rheumatoid Clinical Trial
— CH-1504-201Official title:
A Phase II, Multi-center, Randomized, Double-blind, Methotrexate Controlled Study to Assess the Clinical Efficacy, Safety, and Tolerability of CH-1504 in Subjects With Active Rheumatoid Arthritis
Verified date | April 2013 |
Source | Chelsea Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Interventional |
The purpose of this trial is to assess the clinical effect of CH-1504 at doses of 0.25, 0.5 and 1.0 mg per day in patients with active rheumatoid arthritis by determining the proportion of patients achieving an American College of Rheumatology (ACR) 20% improvement response.
Status | Completed |
Enrollment | 201 |
Est. completion date | June 2009 |
Est. primary completion date | February 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion; To be eligible for inclusion, each patient must fulfill the following criteria: - Patients must be between the ages of 18 and 80; - Have been diagnosed with active rheumatoid arthritis according to ACR criteria; - Have at least 6 swollen joints (max = 66) and 6 tender joints (max = 68) at screening and baseline visits; - Patients must have at least one of the following: - C-reactive protein > 1.0 mg/dl at screening; - erythrocyte sedimentation rate > 20 mm/Hr; - Morning stiffness > 45 min. at screening; - Patients must have blood test values per the following criteria: - ALT, AST < 1.2 U/l x ULN - Albumin > 2.5 g/dl - Prothrombin Time < 1.2 INR - Hb > 9.0 g/dl - Hct > 35% - WBC > 3000 µl (mm3) - Neutrophils > 1000 µl (mm3) - Platelets > 100000 µl - Creatinine < 1.2 mg/dl - Patients must have voluntarily signed the informed consent Exclusion; Patients are not eligible for this study if they fulfill one or more of the following criteria: - Patients who received previous methotrexate therapy; - Patients who received previous therapy with any biologic agent; - Previous biologic therapy for a disease other than RA is permitted so long as their last dose was more than 120 days prior to baseline; - Patients currently taking sulfasalazine; - Previous sulfasalazine therapy is permitted so long as their last dose was more than 30 days prior to baseline; - Patients currently taking hydroxychloroquine; - Previous hydroxychloroquine is permitted so long as their last dose was more than 120 days prior to baseline; - Female patients of child bearing potential who are pregnant or who are not using two methods of contraception (at least one barrier: i.e. condom) with their partner; - Male patients who are sexually active and not using two methods of contraception (at least one barrier: i.e. condom) with their partner; - Patients with any current active infection or infections requiring IV drug therapy within 30 days of baseline or oral therapy within 15 days of Baseline; - Patients that have had any surgical procedures within 30 days of baseline; - Patients with a history of HIV, Hepatitis B or C; - Patients who consume more than 7 units of alcohol per week (1 unit = 5 ounces/150 ml of wine = 1.5 ounces/45 ml spirits = 12 ounces/360 ml of beer); - Patients currently receiving any investigational drug or have received an investigational drug within 30 days of baseline or 5 half-lives of the investigational drug (whichever is longer); - Patients with a history of cancer within the past 5 years other than a successfully treated, non-metastatic cutaneous squamous cell or basal cell carcinoma or cervical cancer in situ; - Patients with a history of, or any, disease associated with an inflammatory arthritis other than RA; - Patients with a chest X-ray that indicates the presence of pulmonary fibrosis (Chest x-ray may be taken with in 28 days of screening); - Patients receiving Probenecid; - Patients who have received any steroid injections within 30 days of baseline; - Patients with concomitant diseases that are unstable (i.e. cardiac, pulmonary) or that may affect drug activity (i.e. absorption, reactions, change in kinetics); - Patients considered by the investigator to be an unsuitable candidate to receive CH-1504; - Wheelchair or bed-bound patients. |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Chelsea Therapeutics |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assess the clinical effect of CH-1504 (0.25, 0.5, and 1.0 mg po daily) by determining the proportion of patients achieving an ACR20 response. | 3 months of treatment | No | |
Secondary | Assess the clinical efficacy of CH-1504 by proportion of patients achieving ACR50 and ACR70 responses. | 3 months of treatment | No | |
Secondary | Assess the clinical efficacy of CH-1504 using EULAR "good" and "moderate" response criteria. | 3 months of treatment | No | |
Secondary | Assess the clinical efficacy of CH-1504 using the difference from baseline of ACR core set and DAS28 of measures. | 3 months of treatment | No | |
Secondary | Evaluate the safety and tolerability of CH-1504 in RA patients as determined by the frequency and severity of adverse events, laboratory abnormalities, and dropouts. | 3 months of treatment | Yes | |
Secondary | Identify the dose response relationship of CH-1504. | 3 months of treatment | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01682512 -
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT00539760 -
A Phase I Rheumatoid Arthritis Study in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03312465 -
Anatomical Shoulder Domelock System Study
|
||
Completed |
NCT01208181 -
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
|
Phase 3 | |
Completed |
NCT03254810 -
Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT01711814 -
A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
|
Phase 2 | |
Completed |
NCT03315494 -
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers
|
Phase 1 | |
Withdrawn |
NCT03241446 -
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
|
Phase 1 | |
Completed |
NCT02748785 -
MTX Discontinuation and Vaccine Response
|
Phase 4 | |
Completed |
NCT02553018 -
Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe
|
Phase 3 | |
Active, not recruiting |
NCT02260778 -
Treat-to-target in RA: Collaboration To Improve adOption and adhereNce
|
N/A | |
Completed |
NCT02569736 -
Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
|
||
Completed |
NCT01750931 -
This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
|
Phase 2 | |
Not yet recruiting |
NCT01154647 -
Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes
|
N/A | |
Withdrawn |
NCT01204138 -
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA
|
Phase 2 | |
Completed |
NCT00913458 -
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
|
Phase 4 | |
Completed |
NCT00975130 -
Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
|
Phase 3 | |
Completed |
NCT00973479 -
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
|
Phase 3 | |
Completed |
NCT00660647 -
Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)
|
Phase 3 | |
Completed |
NCT00550446 -
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
|
Phase 2 |